Crystal structure of the M₅ muscarinic acetylcholine receptor

The human M₅ muscarinic acetylcholine receptor (mAChR) has recently emerged as an exciting therapeutic target for treating a range of disorders, including drug addiction. However, a lack of structural information for this receptor subtype has limited further drug development and validation. Here we...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Proceedings of the National Academy of Sciences - PNAS 2019-12, Vol.116 (51), p.26001-26007
Hauptverfasser: Vuckovic, Ziva, Gentry, Patrick R., Berizzi, Alice E., Hirata, Kunio, Varghese, Swapna, Thompson, Geoff, van der Westhuizen, Emma T., Burger, Wessel A. C., Rahmani, Raphaël, Valant, Celine, Langmead, Christopher J., Lindsley, Craig W., Baell, Jonathan B., Tobin, Andrew B., Sexton, Patrick M., Christopoulos, Arthur, Thal, David M.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The human M₅ muscarinic acetylcholine receptor (mAChR) has recently emerged as an exciting therapeutic target for treating a range of disorders, including drug addiction. However, a lack of structural information for this receptor subtype has limited further drug development and validation. Here we report a high-resolution crystal structure of the human M₅ mAChR bound to the clinically used inverse agonist, tiotropium. This structure allowed for a comparison across all 5 mAChR family members that revealed important differences in both orthosteric and allosteric sites that could inform the rational design of selective ligands. These structural studies, together with chimeric swaps between the extracellular regions of the M₂ and M₅ mAChRs, provided structural insight into kinetic selectivity, where ligands show differential residency times between related family members. Collectively, our study provides important insights into the nature of orthosteric and allosteric ligand interaction across the mAChR family that could be exploited for the design of selective drugs.
ISSN:0027-8424
1091-6490
DOI:10.1073/pnas.1914446116